Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
US Army
Citi
Daiichi Sankyo
Fish and Richardson
Argus Health
Cerilliant
Johnson and Johnson
Covington
Harvard Business School

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 205747

« Back to Dashboard

NDA 205747 describes HUMALOG KWIKPEN, which is a drug marketed by Lilly and Eli Lilly And Co and is included in two NDAs. It is available from four suppliers. There are three patents protecting this drug. Additional details are available on the HUMALOG KWIKPEN profile page.

The generic ingredient in HUMALOG KWIKPEN is insulin lispro recombinant. There are thirty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the insulin lispro recombinant profile page.
Summary for 205747
Tradename:HUMALOG KWIKPEN
Applicant:Eli Lilly And Co
Ingredient:insulin lispro recombinant
Patents:3
Pharmacology for NDA: 205747
Ingredient-typeInsulin
Medical Subject Heading (MeSH) Categories for 205747
Suppliers and Packaging for NDA: 205747
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747 NDA Eli Lilly and Company 0002-7712 0002-7712-99 1 SYRINGE in 1 CARTON (0002-7712-99) > 3 mL in 1 SYRINGE
HUMALOG KWIKPEN insulin lispro recombinant SOLUTION;SUBCUTANEOUS 205747 NDA Eli Lilly and Company 0002-7712 0002-7712-61 1 SYRINGE in 1 CARTON (0002-7712-61) > 3 mL in 1 SYRINGE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength200 UNITS/ML
Approval Date:May 26, 2015TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Jun 11, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.
Patent:➤ SubscribePatent Expiration:Jun 11, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
Patent:➤ SubscribePatent Expiration:Jun 11, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Queensland Health
AstraZeneca
UBS
McKesson
Chinese Patent Office
Daiichi Sankyo
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot